Literature DB >> 10910968

Genomic instability-based transgenic models of prostate cancer.

C Voelkel-Johnson1, D J Voeks, N M Greenberg, R Barrios, F Maggouta, D T Kurtz, D A Schwartz, G M Keller, T Papenbrock, G A Clawson, J S Norris.   

Abstract

To develop animal models that represent the broad spectrum of human prostate cancer, we created transgenic mice with targeted prostate-specific expression of two genes (ECO:RI and c-fos) implicated in the induction of genomic instability. Expression of the transgenes was restricted to prostate epithelial cells by coupling them to the tissue-specific, hormonally regulated probasin promoter (PB). The effects of transgene expression were examined histologically in prostate sections at time points taken from 4 to 24 months of age. The progressive presence of regions of mild-to-severe hyperplasia, low- and high-grade prostatic intra-epithelial neoplasia, and well-differentiated adenocarcinoma was observed in both PBECO:RI lines but no significant pathology was detected in the PBfos line. Prostate tissue of PBECO:RI mice was examined for expression of p53, proliferating cell nuclear antigen (PCNA) and Ki67 at multiple time points. Although p53 does not appear to be mutated, levels of PCNA and Ki67 are elevated and correlate with the severity of the prostatic lesions. Overall, pre-neoplastic and neoplastic stages represented in the PBECO:RI model showed similarity to corresponding early stages of the human disease. This genomic instability-based model will be used to study the mechanisms involved in the early stages of prostate carcinogenesis and to investigate the nature of subsequent events necessary for the progression to advanced disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10910968

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  7 in total

1.  LC/LC-MS/MS of an innovative prostate human epithelial cancer (PHEC) in vitro model system.

Authors:  John D Lapek; James L McGrath; William A Ricke; Alan E Friedman
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2012-03-03       Impact factor: 3.205

2.  Mutations in CHEK2 associated with prostate cancer risk.

Authors:  Xiangyang Dong; Liang Wang; Ken Taniguchi; Xianshu Wang; Julie M Cunningham; Shannon K McDonnell; Chiping Qian; Angela F Marks; Susan L Slager; Brett J Peterson; David I Smith; John C Cheville; Michael L Blute; Steve J Jacobsen; Daniel J Schaid; Donald J Tindall; Stephen N Thibodeau; Wanguo Liu
Journal:  Am J Hum Genet       Date:  2003-01-17       Impact factor: 11.025

Review 3.  Current mouse and cell models in prostate cancer research.

Authors:  Xinyu Wu; Shiaoching Gong; Pradip Roy-Burman; Peng Lee; Zoran Culig
Journal:  Endocr Relat Cancer       Date:  2013-06-24       Impact factor: 5.678

Review 4.  High-grade prostatic intraepithelial neoplasia and prostate cancer risk reduction.

Authors:  Mitchell S Steiner
Journal:  World J Urol       Date:  2003-02-21       Impact factor: 4.226

5.  Correlation of p53 immunoexpression with DNA ploidy and apoptotic index in subsets of prostate cancer: A marker reiterated in progression and recurrence of prostate cancer.

Authors:  Anju Bansal; Anup Gupta; Sunita Saxena
Journal:  South Asian J Cancer       Date:  2015 Apr-Jun

6.  Cytogenetic, Genomic, and Functional Characterization of Pituitary Gonadotrope Cell Lines.

Authors:  Frederique Ruf-Zamojski; Yongchao Ge; Hanna Pincas; Jidong Shan; Yinghui Song; Nika Hines; Kevin Kelley; Cristina Montagna; Pranav Nair; Chirine Toufaily; Daniel J Bernard; Pamela L Mellon; Venugopalan Nair; Judith L Turgeon; Stuart C Sealfon
Journal:  J Endocr Soc       Date:  2019-03-25

7.  Selected aspects of inherited susceptibility to prostate cancer and tumours of different site of origin.

Authors:  Cezary Cybulski
Journal:  Hered Cancer Clin Pract       Date:  2007-09-15       Impact factor: 2.857

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.